Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study-Reference-Cited by-同舟云学术

Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study

Published:2005-06 Issue:16_suppl Volume:23 Page:5-5
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

List A. F.¹,Dewald G.¹,Bennett J.¹,Giagounadis A.¹,Raza A.¹,Feldman E.¹,Powell B.¹,Greenberg P.¹,Zeldis J.¹,Knight R.¹

Affiliation:

1. H. Lee Moffitt Cancer Ctr & Research Inst, Tampa, FL; Mayo Clinic, Rochester, MN; Univ of Rochester, Rochester, NY; St. Johannes Hosp, Duisberg, DE; Univ of MA, Worchester, MA; New York Cornell Medcl Ctr, New York, NY; Wake Forest Univ, Winston Salem, NC; Stanford Univ, Stanford, CA; Celgene Corp, Warren, NJ

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2005.23.16_suppl.5

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of therapeutic options and the management of patients with myelodysplastic syndromes;Expert Review of Hematology;2013-04

2. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes;Leukemia Research;2007-04

3. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes;Current Opinion in Hematology;2007-03

4. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome;Cancer;2007

5. The role of decitabine in the treatment of myelodysplastic syndromes;Expert Opinion on Pharmacotherapy;2006-12-13